Skip to Content
Merck
CN
All Photos(1)

Documents

Safety Information

860952P

Avanti

Lyso GB3 (synthetic)

powder

Sign Into View Organizational & Contract Pricing

Synonym(s):
Globotriaosylsphingosine
Empirical Formula (Hill Notation):
C36H67NO17
CAS Number:
Molecular Weight:
785.91
UNSPSC Code:
12352211
NACRES:
NA.25

Assay

99% (TLC)

form

powder

packaging

package of 1 × 500 μg (860952P-500UG)

manufacturer/tradename

Avanti Polar Lipids

lipid type

sphingolipids

shipped in

dry ice

storage temp.

−20°C

SMILES string

O[C@H]1[C@H](OC[C@H](N)[C@H](O)/C=C/CCCCCCCCCCCCC)O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@@H]([C@H](O)[C@H]2O)O[C@H]3O[C@H](CO)[C@@H]([C@H](O)[C@H]3O)O)[C@@H]1O

General description

Globotriaosylsphingosine (Lyso GB3) is a deacylated form of globotriaosylceramide. It is a circulating bioactive glycolipid.

Application

Globotriaosylsphingosine (Lyso GB3) has been used as a standard in generating calibration curve via ultra-performance liquid chromatography (UPLC) method.

Biochem/physiol Actions

Globotriaosylsphingosine (Lyso GB3) is a potential biomarker of Fabry disease.

Packaging

2 mL Amber Serum Vial with Stopper and Crimp Cap (860952P-500UG)

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

监管及禁止进口产品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

The Fabry disease-associated lipid Lyso-Gb3 enhances voltage-gated calcium currents in sensory neurons and causes pain
Choi L, et al.
Neuroscience Letters, 594, 163-168 (2015)
Lyso-Gb3 activates Notch1 in human podocytes
Sanchez N, et al.
Human Molecular Genetics, 24(20), 5720-5732 (2015)
Rui Quinta et al.
Gene, 536(1), 97-104 (2013-12-18)
Fabry disease is an X-linked lysosomal storage disease (LSD) caused by deficient activity of α-Galactosidase A (α-Gal A). As a result, glycosphingolipids, mainly globotriaosylceramide (Gb3), progressively accumulate in body fluids and tissues. Studies aiming at the identification of secondary lipid

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service